Zynex's (ZYXI) Buy Rating Reaffirmed at HC Wainwright

Zynex (NASDAQ:ZYXI - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright's target price would suggest a potential upside of 205.93% from the company's current price.

Several other equities research analysts also recently issued reports on the stock. Royal Bank Of Canada cut their target price on shares of Zynex from $5.00 to $4.00 and set a "sector perform" rating for the company in a research note on Wednesday, April 30th. LADENBURG THALM/SH SH cut Zynex from a "buy" rating to a "neutral" rating in a report on Wednesday, March 12th.

Zynex Stock Up 2.5%

Zynex stock traded up $0.07 during mid-day trading on Monday, reaching $2.62. The company's stock had a trading volume of 29,554 shares, compared to its average volume of 173,293. The company has a debt-to-equity ratio of 2.87, a quick ratio of 2.63 and a current ratio of 3.46. Zynex has a 12 month low of $1.66 and a 12 month high of $10.62. The business's 50 day simple moving average is $2.27 and its 200 day simple moving average is $4.74. The company has a market capitalization of $79.08 million, a price-to-earnings ratio of -10.90 and a beta of 0.82.

Zynex (NASDAQ:ZYXI - Get Free Report) last released its earnings results on Monday, April 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.09). Zynex had a negative net margin of 4.30% and a negative return on equity of 23.70%. The company had revenue of $26.58 million during the quarter, compared to analyst estimates of $30.83 million. As a group, research analysts anticipate that Zynex will post 0.2 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC increased its stake in shares of Zynex by 138.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,398 shares of the company's stock valued at $27,000 after acquiring an additional 1,975 shares in the last quarter. Alhambra Investment Management LLC acquired a new position in shares of Zynex during the first quarter worth approximately $30,000. Virtu Financial LLC acquired a new stake in Zynex in the 1st quarter valued at $39,000. Deutsche Bank AG increased its stake in Zynex by 172.8% during the 1st quarter. Deutsche Bank AG now owns 19,796 shares of the company's stock valued at $44,000 after purchasing an additional 12,540 shares in the last quarter. Finally, Corton Capital Inc. acquired a new position in Zynex during the first quarter worth $52,000. Institutional investors and hedge funds own 29.68% of the company's stock.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.